Welcome to the Pradaxa® Speaker Website. An online resource for experts in SPAF (Stroke Prevention in Atrial Fibrillation) who have been asked to speak on Pradaxa® at a Boehringer Ingelheim supported meeting.

Use this website to download
ready-to-use presentations.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).
Full prescribing information for dabigatran etexilate (Pradaxa®) can be found at: http://www.pradaxa.co.uk/downloads/pi-spaf.pdf

Pradaxa® 110 mg - Therapeutic Indications

Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation with one or more of the following risk factors:

  • Previous stroke, transient ischemic attack, or systemic embolism (SEE)
  • Left ventricular ejection fraction < 40 %
  • Symptomatic heart failure, ≥ New York Heart Association (NYHA) Class 2
  • Age ≥ 75 years
  • Age ≥ 65 years associated with one of the following: diabetes mellitus, coronary artery disease, or hypertension